Medethics Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 31-07-2024
- Paid Up Capital ₹ 2.80 M
as on 31-07-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.60 M
as on 31-07-2024
- Satisfied Charges ₹ 1.20 Cr
as on 31-07-2024
- Revenue -40.22%
(FY 2023)
- Profit 18.79%
(FY 2023)
- Ebitda 15.03%
(FY 2023)
- Net Worth 0.22%
(FY 2023)
- Total Assets -17.55%
(FY 2023)
About Medethics Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.80 M.
The company currently has active open charges totaling ₹6.60 M. The company has closed loans amounting to ₹1.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sumanta Das and Kusum Das serve as directors at the Company.
- CIN/LLPIN
U51397OR2010PTC011609
- Company No.
011609
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Feb 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Bhubaneswar, Orissa, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Medethics Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumanta Das  | Director | 11-Feb-2010 | Current |
| Kusum Das | Director | 11-Feb-2010 | Current |
Financial Performance of Medethics Pharmaceuticals.
Medethics Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 40.22% decrease. The company also saw a substantial improvement in profitability, with a 18.79% increase in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medethics Pharmaceuticals?
In 2023, Medethics Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kd Corporation (India) Private LimitedActive 12 years 5 monthsSumanta Das and Kusum Das are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 16 Aug 2022 | ₹6.60 M | Open |
Allahabad Bank Creation Date: 06 Feb 2013 | ₹1.20 Cr | Satisfied |
How Many Employees Work at Medethics Pharmaceuticals?
Unlock and access historical data on people associated with Medethics Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medethics Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medethics Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
